TY - JOUR AU - Jain, Rakesh AU - Babcock, Thomas AU - Burtea, Teodor AU - Dirks, Bryan AU - Adeyi, Ben AU - Scheckner, Brian AU - Lasser, Robert PY - 2011 DA - 2011/11/04 TI - Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis JO - Child and Adolescent Psychiatry and Mental Health SP - 35 VL - 5 IS - 1 AB - Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral psychiatric disorder that afflicts children, with a reported prevalence of 2.4% to 19.8% worldwide. Stimulants (methylphenidate [MPH] and amphetamine) are considered first-line ADHD pharmacotherapy. MPH is a catecholamine reuptake inhibitor, whereas amphetamines have additional presynaptic activity. Although MPH and amphetamine can effectively manage ADHD symptoms in most pediatric patients, many still fail to respond optimally to either. After administration, the prodrug stimulant lisdexamfetamine dimesylate (LDX) is converted to l-lysine and therapeutically active d-amphetamine in the blood. The objective of this study was to evaluate the clinical efficacy of LDX in children with ADHD who remained symptomatic (ie, nonremitters; ADHD Rating Scale IV [ADHD-RS-IV] total score > 18) on MPH therapy prior to enrollment in a 4-week placebo-controlled LDX trial, compared with the overall population. SN - 1753-2000 UR - https://doi.org/10.1186/1753-2000-5-35 DO - 10.1186/1753-2000-5-35 ID - Jain2011 ER -